Market Tracker

05/27 5:16pm ET

Myriad Genetics Inc (NASDAQ:MYGN)

34.09
Delayed Data
As of May 27
 +0.66 / +1.97%
Today’s Change
30.30
Today|||52-Week Range
46.24
-21.01%
Year-to-Date
Bull Vs. Bear: Myriad Genetics, Inc.
May 25 / MotleyFool.com - Paid Partner Content
Myriad Genetics Brings myVectra Web Portal for RA Patients
May 17 / Zacks.com - Paid Partner Content
Better Buy: Myriad Genetics, Inc. vs. Exact Sciences
May 17 / MotleyFool.com - Paid Partner Content
Myriad Genetics: Test Revenues Strong, Currency Woes Stay
May 16 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close33.43
Today’s open33.50
Day’s range33.45 - 34.45
Volume855,284
Average volume (3 months)959,108
Market cap$2.4B
Dividend yield--
Data as of 4:00pm ET, 05/27/2016

Growth & Valuation

Earnings growth (last year)-52.00%
Earnings growth (this year)+13.48%
Earnings growth (next 5 years)+14.05%
Revenue growth (last year)-7.08%
P/E ratio23.0
Price/Sales3.50
Price/Book3.63

Competitors

 Today’s
change
Today’s
% change
HZNPHorizon Pharma PLC+0.28+1.72%
IPXLImpax Laboratories I...+0.55+1.67%
LGNDLigand Pharmaceutica...+0.85+0.70%
MDCOMedicines Co+0.45+1.21%
Data as of 4:00pm ET, 05/27/2016

Financials

Next reporting dateAugust 9, 2016
EPS forecast (this quarter)$0.38
Annual revenue (last year)$723.1M
Annual profit (last year)$80.2M
Net profit margin11.09%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Mark C. Capone
Executive Vice President-
International Operations
Gary A. King
Corporate headquarters
Salt Lake City, Utah

Forecasts